Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
International Journal of Dermatology|April 7, 2024
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world studyDario Graceffa, Arianna Zangrilli, Giacomo Caldarola, et al.
Dermatologic Therapy|April 6, 2022
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life studyGiacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual|August 9, 2024
Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio RegionAnnunziata Dattola, Nicoletta Bernardini, Giacomo Caldarola, et al.
Drugs in Context|July 9, 2026
Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio regionFrancesca Feresin, Nicoletta Bernardini, Elena Campione, et al.
Expert Opinion on Biological Therapy|July 19, 2021
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in ItalyArianna Zangrilli, Giacomo Caldarola, Nicoletta Bernardini, et al.
The Journal of Dermatological Treatment|June 9, 2025
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, et al.
Dermatology Practical & Conceptual|May 22, 2025
Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology OutcomesTonia Samela, Gaia Moretta, Alessia Provini, et al.
Dermatology (Basel, Switzerland)|April 23, 2025
Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive AreasNiccolò Gori, Marco Galluzzo, Andrea Chiricozzi, et al.
Drugs in Context|September 15, 2025
Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptomsAnnunziata Dattola, Nicoletta Bernardini, Jasmine Anedda, et al.
Dermatology Practical & Conceptual|March 30, 2026
Effectiveness and Safety of Deucravacitinib in Moderate-to-Severe Psoriasis: an Italian Multicenter Real-Life Study in the Lazio RegionAnnunziata Dattola, Francesca Paola Sasso, Giorgio Marotta, et al.
Pageof 5